AD Pipeline Update: Target Enrollment Complete in Phase 2b Trial of Nectar’s Rezpegaldesleukin in AD
Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed that rezpegaldesleukin safely and […]